Sana Biotechnology Inc. (SANA) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Sana Biotechnology Inc. (SANA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

3.63

0.17 (4.91%)

At close: Jan 14, 2025, 3:59 PM

3.65

0.41%

Pre-market Jan 15, 2025, 06:26 AM EST

undefined% (undefined)

Bid	3.6
Market Cap	811.58M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.4
PE Ratio (ttm)	-2.6
Forward PE	n/a
Analyst	Strong Buy

Ask	3.66
Volume	9,351,707
Avg. Volume (20D)	5,398,832
Open	3.43
Previous Close	3.46
Day's Range	3.20 - 3.81
52-Week Range	1.52 - 12.00
Beta	undefined

About SANA

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 4, 2021

Employees 328

Stock Exchange NASDAQ

Ticker Symbol SANA

Website https://www.sana.com

Analyst Forecast

According to 4 analyst ratings, the average rating for SANA stock is "Strong Buy." The 12-month stock price forecast is $13, which is an increase of 257.63% from the latest price.

Buy 75.00%

Hold 25.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 week ago · Source

+160.61%

Sana Biotechnology shares are trading higher after... Unlock content with Pro Subscription

1 week ago · Source

-5.71%

Sana Biotechnology shares are trading higher after the company announced positive clinical trial results from its type 1 diabetes study of islet cell transplantation without immunosuppression.

News

5 days ago · zacks.com

SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data

Sana stock soars in a week following positive initial data from a first-in-human study of investigational cell therapy, UP421, in diabetes patients.

1 week ago · proactiveinvestors.com

Sana Biotechnology skyrockets 200% on positive diabetes study data

Sana Biotechnology Inc skyrocketed over 200% on Wednesday after unveiling positive results from its first in-human diabetes trial. No safety issues were observed four weeks after transplanting Sana's ...

1 week ago · seekingalpha.com

Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success

Sana Biotechnology, Inc. stock will be surging today after the company showed it can safely administer its allogeneic cell therapy for diabetes to a patient with no immunosuppression. Engineered cells...

1 week ago · benzinga.com

Sana Biotechnology Stock Surges Over 200% On Wednesday - Here's Why

On Tuesday, Sana Biotechnology Inc SANA released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune (HIP) t...

1 week ago · https://thefly.com

Citi keeps $15 target on Sana, says data 'potentially transformative'

Citi says that while the wait for Sana Biotechnology's initial type 1 diabetes data was long, the "reward was well worth it as Sana has delivered what looks to be potentially transformative data," the...

1 week ago · https://thefly.com

H.C. Wainwright ups Sana target after 'best case scenario' data

H.C. Wainwright raised the firm's price target on Sana Biotechnology to $11 from $8 and keeps a Buy rating on the shares. The firm increased its probability of sucess for SC451 to 15% from 10% based o...

1 week ago · barrons.com

This Biotech Stock Just Soared 240%. Why It Can Go Higher.

The shares are at about $5 now, and strategists see a chance they could go to $10.

1 month ago · seekingalpha.com

Sana: Major Inflection Point For SC291 In 2025 Targeting Lupus

Sana Biotechnology results from the phase 1 study using SC291 for the treatment of patients with SLE are expected in 2025. The FDA's Fast Track Designation for SC291 could expedite its review, address...

1 month ago · seekingalpha.com

Sana Biotechnology: The Story Becomes Murkier

Sana Biotechnology, Inc.'s stock has dropped from around $9 to under $2.50 since mid-March, when we last took a look at this engineered-cell therapy concern. Earlier this month, the company suspended ...

2 months ago · zacks.com

Here's Why Sana (SANA) Could be Great Choice for a Bottom Fisher

Sana (SANA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend ...

2 months ago · zacks.com

Down -24.69% in 4 Weeks, Here's Why Sana (SANA) Looks Ripe for a Turnaround

Sana (SANA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earn...